TBG DIAGNOSTICS LIMITED
ASX
AU Flag
TDL

TDL
TBG DIAGNOSTICS LIMITED
AU Flag
ASX
 
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E

TDL Stock Chart

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 41
TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out